SCHEMBL128657

SCHEMBL128657

[CH2]CCCCN(CCCC)CCCC

nearest known ligand 0.38

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
KDM5A P29375 4/20 0.38
DNM1 Q05193 3/20 0.38
PHF8 Q9UPP1 2/20 0.36
KDM4C Q9H3R0 2/20 0.36
CA12 O43570 2/20 0.36
CA1 P00915 2/20 0.36
CA9 Q16790 2/20 0.36
MAPT P10636 1/20 0.34
KCNH2 Q12809 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL130956 0.97 DNM1 (0.42) KDM5ADNM1PHF8KDM4CCA12
SCHEMBL5397414 0.97 DNM1 (0.42) KDM5ADNM1PHF8KDM4CCA12
SCHEMBL21065780 0.97 KDM5A (0.37) KDM5ADNM1PHF8KDM4CCA12
SCHEMBL5381080 0.97 DNM1 (0.42) KDM5ADNM1PHF8KDM4CCA12
SCHEMBL317338 0.97 DNM1 (0.42) KDM5ADNM1PHF8KDM4CCA12
SCHEMBL5384597 0.97 DNM1 (0.42) KDM5ADNM1PHF8KDM4CCA12
SCHEMBL8410101 0.97 DNM1 (0.42) KDM5ADNM1PHF8KDM4CCA12
SCHEMBL21084357 0.95 DNM1 (0.40) KDM5ADNM1PHF8KDM4CCA12
SCHEMBL21065751 0.95 DNM1 (0.40) KDM5ADNM1PHF8KDM4CCA12
SCHEMBL2045798 0.94 DNM1 (0.43) KDM5ADNM1PHF8KDM4CCA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461375-B2 Method for the continuous production of alkyl(meth)acrylates with multiple catalyst recycling EVONIK RÖHM GMBH (DE) 2013-06-11 US disclosed
US-8450319-B2 Pyrrolopyridazinone compound UBE INDUSTRIES, LTD. (JP) 2013-05-28 US disclosed
EP-1583733-B1 IMPROVED METHOD FOR THE CONTINUOUS PRODUCTION OF ALKYL(METH)ACRYLATES WITH MULTIPLE CATALYST RECYCLING EVONIK ROEHM GMBH (DE) 2013-04-24 EP disclosed
EP-1399409-B1 METHOD FOR PRODUCING (METH)ACRYLIC ACID ESTERS BASF SE (DE) 2012-10-31 EP disclosed
EP-1982986-B1 PYRROLOPYRIDAZINONE COMPOUND AS PDE4 INHIBITOR UBE INDUSTRIES (JP) 2012-03-07 EP disclosed
EP-1745002-B1 NOVEL COMPOUNDS, THEIR PREPARATION AND USE HIGH POINT PHARMACEUTICALS LLC (US) 2010-11-03 EP disclosed
US-20100210653-A1 Novel Compounds, Their Preparations and Use HIGH POINT PHARMACEUTICALS, LLC (US) 2010-08-19 US disclosed
US-20090036453-A1 Pyrrolopyridazinone Compound UBE INDUSTRIES, LTD. (JP) 2009-02-05 US disclosed
EP-1982986-A1 PYRROLOPYRIDAZINONE COMPOUND Ube Industries, Ltd. (JP) 2008-10-22 EP disclosed
US-20080114036-A1 Novel Compounds, Their Preparations And Use NOVO NORDISK A/S (DK) 2008-05-15 US disclosed
WO-2005105725-A1 NOVEL COMPOUNDS, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 2005-11-10 WO disclosed
EP-1583733-A1 IMPROVED METHOD FOR THE CONTINUOUS PRODUCTION OF ALKYL(METH)ACRYLATES WITH MULTIPLE CATALYST RECYCLING Röhm GmbH & Co. KG (DE) 2005-10-12 EP disclosed
US-20040171868-A1 Method for producing (meth) acrylic acid esters BASF AKTIENGESELLSCHAFT (DE) 2004-09-02 US disclosed
CN-1525953-A Method for producing (meth) acrylic acid esters �����ɷ� 2004-09-01 CN disclosed
US-20040158096-A1 Method for producing (meth)acrylic acid esters BASF AKTIENGESELLSCHAFT (DE) 2004-08-12 US disclosed
WO-2004063140-A1 IMPROVED METHOD FOR THE CONTINUOUS PRODUCTION OF ALKYL(METH)ACRYLATES WITH MULTIPLE CATALYST RECYCLING Röhm GmbH & Co. KG (DE) 2004-07-29 WO disclosed
EP-1399409-A1 METHOD FOR PRODUCING (METH)ACRYLIC ACID ESTERS BASF AKTIENGESELLSCHAFT (DE) 2004-03-24 EP disclosed
EP-1399408-A1 METHOD FOR PRODUCING (METH)ACRYLIC ACID ESTERS BASF AKTIENGESELLSCHAFT (DE) 2004-03-24 EP disclosed
WO-2002100814-A1 METHOD FOR PRODUCING (METH)ACRYLIC ACID ESTERS BASF AKTIENGESELLSCHAFT (DE) 2002-12-19 WO disclosed
WO-2002100815-A1 METHOD FOR PRODUCING (METH)ACRYLIC ACID ESTERS BASF AKTIENGESELLSCHAFT (DE) 2002-12-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040171868-A1 Method for producing (meth) acrylic acid esters ADH1A, ADH5, ADH1C KDM5A 1325/4885DNM1 1568/4885PHF8 1683/4885
US-20100210653-A1 Novel Compounds, Their Preparations and Use PPARG, PPARD, PPARA KDM5A 4556/4885DNM1 2246/4885PHF8 4297/4885
US-20080114036-A1 Novel Compounds, Their Preparations And Use PPARG, PPARD, GPR119 KDM5A 4551/4885DNM1 1964/4885PHF8 4433/4885
US-20090036453-A1 Pyrrolopyridazinone Compound CBR3, CBR1, CYC1 KDM5A 1260/4885DNM1 3297/4885PHF8 3868/4885
US-20040158096-A1 Method for producing (meth)acrylic acid esters ADH1A, ADH5, ADH1C KDM5A 2147/4885DNM1 2335/4885PHF8 1409/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.